The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking (Sweed)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Gelderland
-
Wageningen, Gelderland, Netherlands, 6703 HD
- Wageningen University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI: 18.5 - 25 kg/m2
- Incidental cannabis use for at least one year, at least four times per year, but less than once a week.
- Dutch-speaking
- Willing to comply with the study procedures
- Having given written informed consent
Exclusion Criteria:
- Not meeting the inclusion criteria
- Restraint eating (men: score > 2.90)
- Lack of appetite
- Having difficulties with swallowing/eating
- Usage of an energy restricted diet during the last two months
- Weight loss or weight gain of 5kg or more during the last two months
- Stomach or bowel disease
- Diabetes, thyroid disease, other endocrine disorders
- Use of daily medication except paracetamol
- Having taste or smell disorders (self-report)
- Being allergic/intolerant for products under study
- Previously experienced an adverse reaction to cannabinoids (e.g. anxiety, paranoia, nausea)
- Having (had) a schizophrenia or other psychotic illness
- Having a family history of schizophrenia or other psychotic illness
- Working at the Division of Human Nutrition (WUR)
- Current participation in other research from the Division of Human Nutrition (WUR)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: T-C-P
Order of administrations: tetrahydrocannabinol - cannabidiol - placebo
|
Other Names:
Other Names:
|
|
Experimental: T-P-C
Order of administrations: tetrahydrocannabinol - placebo - cannabidiol
|
Other Names:
Other Names:
|
|
Experimental: C - T - P
Order of administrations: cannabidiol - tetrahydrocannabinol - placebo
|
Other Names:
Other Names:
|
|
Experimental: C - P - T
Order of administrations: cannabidiol - placebo - tetrahydrocannabinol
|
Other Names:
Other Names:
|
|
Experimental: P - T - C
Order of administrations: placebo - tetrahydrocannabinol - cannabidiol
|
Other Names:
Other Names:
|
|
Experimental: P - C - T
Order of administrations: placebo - cannabidiol - tetrahydrocannabinol
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relation between sweet taste intensity and liking
Time Frame: 15 minutes after intervention
|
The main study parameter is the relation between sucrose intensity scaling (psychophysics) and liking (psychohedonics) of drinks with the different sucrose concentrations.
These scores will be assessed after six participants and at end of the study.
|
15 minutes after intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ranking order of pleasantness of different drinks with different levels of sucrose.
Time Frame: 25 minutes after intervention
|
Ranking order will be assessed after 6 participants and at end of the study
|
25 minutes after intervention
|
|
Preferences for different kinds of foods
Time Frame: 45 minutes after intervention (15 minutes after top-up dose)
|
Preference for foods high in one of three macronutrients (carbohydrate, protein, fat) or low in energy
|
45 minutes after intervention (15 minutes after top-up dose)
|
|
Ad libitum intake
Time Frame: 35 minutes after intervention (5 minutes after top-up dose)
|
Ad libitum intake of a chocolate-based drink
|
35 minutes after intervention (5 minutes after top-up dose)
|
|
Change of plasma levels of (endo-)cannabinoids and satiety hormones
Time Frame: One hour after intervention
|
One hour after intervention
|
|
|
Polymorphisms
Time Frame: At test session, i.e., 2 weeks before first intervention
|
The genetic determination of the enzymes responsible for the metabolism of THC and CBD.
|
At test session, i.e., 2 weeks before first intervention
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Descriptives
Time Frame: At inclusion of participants
|
General subject characteristics, e.g age, restrained eating score and other lifestyle and medical parameters
|
At inclusion of participants
|
|
Appetite ratings
Time Frame: During each test session
|
During each test session, appetite ratings will be assessed at several time points
|
During each test session
|
|
Subjective feelings
Time Frame: During each test session
|
During each test sessions, participants will rate the effects of the intervention.
|
During each test session
|
|
Perception
Time Frame: 20 minutes after intervention
|
Participants will rate the intensity of different shades of grey.
|
20 minutes after intervention
|
|
Sweet taste intensity
Time Frame: 15 minutes after intervention
|
Sucrose intensity of drinks (psychophysics) of drinks with different sucrose concentrations.
This will be assessed after six participants and at end of the study.
|
15 minutes after intervention
|
|
Liking of sweet taste
Time Frame: 15 minutes after intervention
|
Liking (psychohedonics) of drinks with the different sucrose concentrations.
This will be assessed after six participants and at end of the study.
|
15 minutes after intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Suzanne EM de Bruijn, MSc, Wageningen University
- Study Chair: Gerry Jager, Dr., Wageningen University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Psychotropic Drugs
- Anticonvulsants
- Hallucinogens
- Cannabinoid Receptor Agonists
- Cannabinoid Receptor Modulators
- Dronabinol
- Cannabidiol
Other Study ID Numbers
Other Study ID Numbers
- NL44758.081.13
- 2013-002555-14 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.